The Food and Drug Administration FDA has recently announced that it has plans of reviewing direct-to-consumer prescription drug advertisements.
The FDA and the pharmaceutical industry are facing pressure to alter advertising practices for drugs, with agency research showing that many physicians and consumers think drug ads exaggerate benefits and do not adequately disclose risks. FDA's last broad review of pharmaceutical industry advertising led to revised guidelines in 1997 that "set off a surge in ads say reports.
The agency says that it will hold a public meeting to gather information and opinions about DTC drug ads, according to people with information on the issue. Such sessions typically serve as the first formal step in setting new rules. FDA says it is also likely to consider whether drug advertisements provide balanced information about the risks and benefits of specific medications and also look into certain areas to see if it needs to adjust any current requirements for disclosure of drugs side effects .
Reports say the review might also encompass promotions of medical devices as well as review advertising in digital media.